As part of its advocacy program in Europe, ACRO submits regulatory comments to European officials. This comment letter, submitted by ACRO to EMA in 2019 about Comments on draft Guideline on the quality requirements for drug-device combinations (EMA/CHMP/QWP/BWP/259165/2019) can be found below.